H. Lundbeck A/S (HLBBF)
OTCMKTS
· Delayed Price · Currency is USD
5.60
0.00 (0.00%)
At close: Jan 21, 2025
H. Lundbeck Revenue
In the year 2024, H. Lundbeck had annual revenue of 22.00B DKK with 10.51% growth. H. Lundbeck had revenue of 5.54B in the quarter ending December 31, 2024, with 11.31% growth.
Revenue
22.00B DKK
Revenue Growth
+10.51%
P/S Ratio
n/a
Revenue / Employee
3.86M DKK
Employees
5,707
Market Cap
5.33B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22.00B | 2.09B | 10.51% |
| Dec 31, 2023 | 19.91B | 1.67B | 9.13% |
| Dec 31, 2022 | 18.25B | 1.95B | 11.95% |
| Dec 31, 2021 | 16.30B | -1.37B | -7.77% |
| Dec 31, 2020 | 17.67B | 636.00M | 3.73% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| SS Innovations International | 16.04M |
| Veradigm | 1.53B |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| BioStem Technologies | 210.49M |
| SANUWAVE Health | 29.30M |
H. Lundbeck News
- 6 weeks ago - Lundbeck's Appreciation Potential Is Closely Tied To A High-Risk Clinical Pipeline (Rating Upgrade) - Seeking Alpha
- 3 months ago - Longboard Pharmaceuticals HSR waiting period expires for Lundbeck deal - Seeking Alpha
- 4 months ago - Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management - Seeking Alpha
- 4 months ago - NVIDIA, Trump Media & Technology, Bausch + Lomb, Sirius XM And Other Big Stocks Moving Higher On Monday - Benzinga
- 4 months ago - Top 1% Biotech Longboard Scores A $2.6 Billion Deal And Skyrockets To A Record - Investor's Business Daily
- 4 months ago - Longboard Pharmaceuticals’ stock soars amid Lundbeck’s $2.6 billion deal to acquire the company - MarketWatch
- 4 months ago - Lundbeck to Acquire Longboard Pharmaceuticals (LBPH) for $2.6 Billion - GuruFocus
- 4 months ago - Why Is Epilepsy Focused Longboard Pharmaceuticals Stock Trading Higher On Monday? - Benzinga